8 completed, 6 recruiting, 2 enrolling by invitation, 2 unknown. 20 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 8, Recruiting 6, Enrolling by invitation 2, Unknown 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 3, Recruiting 1 |
Follow Myotonic Disorders: new trials by email Literature Review of Myotonic Disorders trials Research Report on Myotonic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping AOC 1044, Placebo - Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy) | Phase 3 | Recruiting | Avidity Biosciences, Inc. | 70 | 2026-09-01 | 2026-11-10 |
| Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO) Zeleciment Rostudirsen (DYNE-251), Placebo - Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne | Phase 3 | Recruiting | Dyne Therapeutics | 90 | 2026-06-01 | 2026-05-27 |
| Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 zeleciment basivarsen (DYNE-101), Placebo - Myotonic Dystrophy Type 1 (DM1), DM1 | Phase 3 | Recruiting | Dyne Therapeutics | 150 | 2026-05-14 | 2026-11-13 |
| An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study. Mexiletine granules for prolonged-release oral suspension - Myotonic Dystrophy | Phase 3 | Enrolling by invitation | Lupin Ltd. | 176 | 2025-09-12 | 2026-01-26 |
| Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 Del-desiran (AOC 1001) - Myotonic Dystrophy Type 1, DM1 | Phase 3 | Enrolling by invitation | Avidity Biosciences, Inc. | 199 | 2025-06-26 | 2026-08-19 |
| The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Mexiletine granules for prolonged-release oral suspension, Placebo - Myotonic Dystrophy | Phase 3 | Recruiting | Lupin Ltd. | 176 | 2025-02-13 | 2026-09-24 |
| Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease) Treatment taken - Steinert's Disease, Myotonic Dystrophy 1 | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 142 | 2024-11-29 | 2025-11-24 |
| Global Study of Del-desiran for the Treatment of DM1 AOC 1001 (del-desiran), Placebo - DM1, Myotonic Dystrophy | Phase 3 | Completed | Avidity Biosciences, Inc. | 159 | 2024-05-30 | 2026-09-01 |
| Home-based Training and Supplementation in DM1 Patients Mult-ingredient supplement, Placebo, Concurrent exercise training - Myotonic Dystrophy 1 | Phase 3 | Unknown | McMaster University | 60 | 2024-01-01 | 2023-10-19 |
| Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2 Mexiletine 167 mg, Placebo - Myotonic Dystrophy Type 1 and Type 2 | Phase 3 | Withdrawn | Lupin Ltd. | 2021-09-03 | 2024-05-06 | |
| Open Label Study in Adolescents and Children With Myotonic Disorders Mexiletine - Myotonic Dystrophy | Phase 3 | Completed | Lupin Ltd. | 12 | 2021-09-03 | 2024-11-25 |
| Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy Tideglusib - Congenital Myotonic Dystrophy | Phase 2 / Phase 3 | Recruiting | AMO Pharma Limited | 76 | 2021-08-23 | 2025-05-28 |
| Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy Tideglusib, Placebo - Congenital Myotonic Dystrophy | Phase 2 / Phase 3 | Completed | AMO Pharma Limited | 56 | 2021-03-03 | 2025-10-08 |
| Lamotrigine as Treatment of Myotonia Lamotrigine, Placebo - Dystrophia Myotonica Type 1, Myotonia Congenita | Phase 3 | Completed | Grete Andersen, MD | 27 | 2013-11-01 | 2016-04-25 |
| Mexiletine and Non Dystrophic Myotonias Mexiletine, placebo - Non-dystrophic Myotonias, Paramyotonia Congenita | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 24 | 2011-06-01 | 2015-01-13 |
| Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Bilevel pressure ventilator - Myopathy, Muscular Weakness | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 77 | 2010-10-01 | 2017-11-20 |
| Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders mechanical insufflation - exsufflation, Standard respiratory physiotherapy - Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 14 | 2009-06-01 | 2015-05-28 |
| Methylphenidate in Myotonic Dystrophy Type 1 Methylphenidate, Placebo - Dystrophia Myotonica 1 | Phase 2 / Phase 3 | Completed | Laval University | 28 | 2008-06-01 | 2011-08-23 |
| Efficacy and Safety of DHEA for Myotonic Dystrophy dehydroepiandrosterone 100 and 400 mg - Myotonic Dystrophy | Phase 2 / Phase 3 | Completed | University of Versailles | 75 | 2004-11-01 | 2010-04-06 |
| Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders dichlorphenamide - Paralysis, Hyperkalemic Periodic, Hypokalemic Periodic Paralysis | Phase 3 | Completed | National Center for Research Resources (NCRR) | 64 | 1992-06-01 | 2005-06-24 |
Myotonic Dystrophy (17) · Myotonia (4) · Muscular Dystrophy, Duchenne (3) · Myotonia Congenita (3) · Neuromuscular Diseases (3) · Disorders of Excessive Somnolence (2) · Genetic Diseases, Inborn (2) · Muscular Diseases (2) · Muscular Dystrophies (2) · Paralysis, Hyperkalemic Periodic (2) · Amyotrophic Lateral Sclerosis (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, X-Linked (1) · Hypokalemic Periodic Paralysis (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (19) · Heredodegenerative Disorders, Nervous System (19) · Musculoskeletal Diseases (19) · Nervous System Diseases (19) · Neurodegenerative Diseases (19) · Genetic Diseases, Inborn (18) · Muscular Diseases (18) · Muscular Disorders, Atrophic (17) · Neuromuscular Diseases (17) · Muscular Dystrophies (16) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Neurologic Manifestations (5) · Neuromuscular Manifestations (5)
Mexiletine (3) · tideglusib (2) · Dichlorphenamide (1) · Lamotrigine (1) · Methylphenidate (1)
Assistance Publique - Hôpitaux de Paris (4) · Lupin Ltd. (4) · Avidity Biosciences, Inc. (3) · AMO Pharma Limited (2) · Dyne Therapeutics (2) · Grete Andersen, MD (1) · Laval University (1) · McMaster University (1) · National Center for Research Resources (NCRR) (1) · University of Versailles (1)
France (10) · Canada (7) · United Kingdom (7) · Denmark (6) · Germany (6) · Italy (6) · Spain (6) · United States (6) · Australia (4) · Belgium (4) · Netherlands (4) · Japan (3) · New Zealand (3) · Poland (1)
Bertrand Fontaine, MD, PhD (1) · Grete Andersen, MD (1) · Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM (1) · Jack J Puymirat, MD (1) · Jerry R. Mendell (1) · Joseph P Horrigan, MD (1) · Savine Vicart, MD (1)
PMID 18678823, PMID 22578232, PMID 39555632
2025 (2), 2016 (1), 2023 (1)